{"log_id": 1541033692809429614, "direction": 0, "words_result_num": 32, "words_result": [{"probability": {"variance": 1e-06, "average": 0.999319, "min": 0.996858}, "location": {"width": 705, "top": 158, "height": 45, "left": 92}, "words": "些动物中,引起心功能不全的最重要体征包括心肌肥厚和心脏扩大"}, {"probability": {"variance": 1.3e-05, "average": 0.9981, "min": 0.989255}, "location": {"width": 153, "top": 218, "height": 29, "left": 101}, "words": "【药代动力学】"}, {"probability": {"variance": 2e-06, "average": 0.999203, "min": 0.993899}, "location": {"width": 845, "top": 253, "height": 44, "left": 141}, "words": "伊马替尼的药代动力学是在25~1000mg剂量范围,在单剂量和达稳态后评价的"}, {"probability": {"variance": 6.9e-05, "average": 0.996034, "min": 0.970422}, "location": {"width": 923, "top": 299, "height": 46, "left": 140}, "words": "伊马替尼剂量在25~1000mg范围内,其平均曲线下面积(AUC)的增加与剂量存在比例性"}, {"probability": {"variance": 0.000289, "average": 0.992849, "min": 0.930794}, "location": {"width": 566, "top": 354, "height": 39, "left": 93}, "words": "关系。重复给药的药物累积量在达稳态时为1.5-2.5倍"}, {"probability": {"variance": 0, "average": 0.999891, "min": 0.999801}, "location": {"width": 51, "top": 412, "height": 27, "left": 95}, "words": "吸收"}, {"probability": {"variance": 3e-06, "average": 0.998955, "min": 0.992783}, "location": {"width": 920, "top": 443, "height": 44, "left": 144}, "words": "伊马替尼的平均绝对生物利用度为98%,口服后血浆伊马替尼AUC的变异系数波动在"}, {"probability": {"variance": 0.000376, "average": 0.991694, "min": 0.915769}, "location": {"width": 856, "top": 492, "height": 44, "left": 102}, "words": "4%~60%之间。与空腹时比较,高脂饮食后本药吸收率轻微降低(Cmax减少11%"}, {"probability": {"variance": 0, "average": 0.999809, "min": 0.999742}, "location": {"width": 46, "top": 496, "height": 25, "left": 1018}, "words": "延后"}, {"probability": {"variance": 6.4e-05, "average": 0.993304, "min": 0.970208}, "location": {"width": 324, "top": 553, "height": 28, "left": 97}, "words": "1.5小时),AUC略减少(7.4%)"}, {"probability": {"variance": 0, "average": 0.999656, "min": 0.999356}, "location": {"width": 52, "top": 603, "height": 27, "left": 98}, "words": "分布"}, {"probability": {"variance": 0.003816, "average": 0.988851, "min": 0.603716}, "location": {"width": 920, "top": 635, "height": 43, "left": 147}, "words": "约95%与血浆蛋白结合,绝大多数是与白蛋白结合,少部分与a-酸性糖蛋白结合,只有"}, {"probability": {"variance": 0.001546, "average": 0.992145, "min": 0.741208}, "location": {"width": 968, "top": 684, "height": 42, "left": 98}, "words": "极少部分与脂蛋白结合。整个机体内的总体分布浓度较高,分布容积为4.9L/kg体重,但红"}, {"probability": {"variance": 8e-06, "average": 0.998678, "min": 0.986804}, "location": {"width": 970, "top": 731, "height": 45, "left": 99}, "words": "细胞内分布比率较低。体内组织中有关药物分布情况仅来源于临床前的资料。肾上腺和性腺"}, {"probability": {"variance": 3e-06, "average": 0.999119, "min": 0.991993}, "location": {"width": 463, "top": 785, "height": 38, "left": 100}, "words": "中摄取水平高,中枢神经系统中摄取水平低"}, {"probability": {"variance": 0, "average": 0.99985, "min": 0.999844}, "location": {"width": 52, "top": 842, "height": 26, "left": 100}, "words": "代谢"}, {"probability": {"variance": 1e-06, "average": 0.999314, "min": 0.995952}, "location": {"width": 923, "top": 874, "height": 44, "left": 150}, "words": "人体内主要循环代谢产物是N去甲基哌嗪衍生物,在体外其药效与原药相似。该代谢物"}, {"probability": {"variance": 0.003909, "average": 0.986499, "min": 0.569721}, "location": {"width": 960, "top": 923, "height": 44, "left": 101}, "words": "的血浆AUC是原药甲磺酸伊马替尼AUC的16%伊马替尼是CYP3A4的底物,又是CYP3A4"}, {"probability": {"variance": 0.001424, "average": 0.988501, "min": 0.742915}, "location": {"width": 968, "top": 969, "height": 48, "left": 104}, "words": "CYP2D6、CYP2C9和CYP2C19的抑制剂,因此,可影响合用药物的代谢。见【药物相互作"}, {"probability": {"variance": 0, "average": 0.99912, "min": 0.998916}, "location": {"width": 46, "top": 1034, "height": 27, "left": 105}, "words": "用】"}, {"probability": {"variance": 8e-06, "average": 0.997947, "min": 0.993919}, "location": {"width": 123, "top": 1006, "height": 98, "left": 793}, "words": "限公司"}, {"probability": {"variance": 0, "average": 0.999497, "min": 0.999309}, "location": {"width": 49, "top": 1082, "height": 27, "left": 105}, "words": "消除"}, {"probability": {"variance": 1e-06, "average": 0.99933, "min": 0.993376}, "location": {"width": 922, "top": 1114, "height": 45, "left": 152}, "words": "伊马替尼的消除半衰期为18小时,其活性代谢产物半衰期为40小时,7天内约可排泄"}, {"probability": {"variance": 0.000685, "average": 0.99257, "min": 0.836696}, "location": {"width": 969, "top": 1162, "height": 47, "left": 106}, "words": "所给药物剂量的81%,其中从粪便中排泄68%,尿中排泄13%。约25%为原药(尿中5%,大"}, {"probability": {"variance": 3e-06, "average": 0.998922, "min": 0.992526}, "location": {"width": 812, "top": 1212, "height": 44, "left": 105}, "words": "便中20%),其余为代谢产物,在粪便和尿中活性代谢产物和原药的比例相似"}, {"probability": {"variance": 1.6e-05, "average": 0.998436, "min": 0.985706}, "location": {"width": 272, "top": 1268, "height": 37, "left": 106}, "words": "特殊患者群的药代动力学"}, {"probability": {"variance": 1e-06, "average": 0.999211, "min": 0.99468}, "location": {"width": 894, "top": 1306, "height": 45, "left": 156}, "words": "成人群体药代动力学研究表明,性别对药代动力学无影响,体重的影响也可略而不计"}, {"probability": {"variance": 2e-06, "average": 0.99921, "min": 0.997032}, "location": {"width": 96, "top": 1369, "height": 30, "left": 112}, "words": "儿童用药"}, {"probability": {"variance": 1.2e-05, "average": 0.998317, "min": 0.980018}, "location": {"width": 923, "top": 1406, "height": 48, "left": 156}, "words": "儿童和青少年260mg/m2和340mg/m2的使用剂量会产生同样的药物暴露,分别相当于成"}, {"probability": {"variance": 0.004127, "average": 0.987192, "min": 0.545297}, "location": {"width": 968, "top": 1456, "height": 46, "left": 111}, "words": "人的400mg和600mg.以340mg/m2天的剂量经每日一次重复给药后,第8天和第1天的AUC"}, {"probability": {"variance": 0.001791, "average": 0.986141, "min": 0.818333}, "location": {"width": 348, "top": 1508, "height": 39, "left": 138}, "words": "4)比揭示出有1.7倍的药物蓄积。"}, {"probability": {"variance": 0.001176, "average": 0.963156, "min": 0.928864}, "location": {"width": 20, "top": 1608, "height": 20, "left": 589}, "words": "21"}], "language": 3}